Navigation Links
Human Genome Sciences Advances Oncology Portfolio
Date:4/16/2008

ombination with Velcade

(bortezomib) in advanced multiple myeloma, and expects to have data

available in the third quarter of 2008.

-- In December 2007, HGS initiated dosing of approximately 105 patients in

a randomized Phase 2 trial of HGS-ETR1 in combination with paclitaxel

and carboplatin as first-line therapy in advanced non-small cell lung

cancer, and expects to have data available in 2009.

-- Today, HGS announced that it plans by mid-2008 to initiate a randomized

Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in

hepatocellular cancer. The study in hepatocellular cancer will begin

with a safety lead-in to assure the safety of this combination therapy

in patients with hepatocellular cancer who are infected with hepatitis

C.

About the HGS IAP Inhibitor Program

In December 2007, the HGS oncology portfolio was further strengthened by a licensing and collaboration agreement between HGS and Aegera Therapeutics Inc. This agreement provides HGS with exclusive worldwide rights (excluding Japan) to develop and commercialize HGS1029 (formerly AEG40826) and other small- molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Preclinical studies of HGS1029 in combination with the Company's TRAIL receptor antibodies demonstrated dramatic synergistic activity against a number of cancer types. HGS1029 has also shown significant anti-tumor activity alone and in combination with other agents in a broad range of cancers. HGS expects to initiate a Phase 1 clinical trial of HGS1029 by mid-2008 and plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapeutic agents.

About HGS-ETR1 and HGS-ETR2

HGS-ETR1 and HGS-ETR2 are agonistic human monoclonal antibodies that directly induce cancer-cell death by specifically binding to and activating th
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
(Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing ... from the Ministry of Health, Labour and Welfare Kinki Bureau ... The fact that R- Japan received ... Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 ... stem cell manufacturing service to medical institutions. As of November ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... that does not sacrifice selectivity to achieve faster flow rates in comparison to ... pores with significant open space to allow easy liquid flow while trapping particulates ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... Highlight Applications in Inventory Management, Disposables ... WESTMINSTER, Colo., Dec. 11 , WHAT: This presentation identifies ... medical devices and supplies and explains how embedded RFID ... a way that enhances safety ...
... - TB-402 Shows Clear Promise as a Stable ... ThromboGenics NV (Euronext Brussels:THR), a biotechnology company,focused on ... of the,first Phase I trial of TB-402 were ... (ASH) 49th Annual Meeting in Atlanta,Georgia, USA. TB-402 ...
... ALACHUA, Fla., Dec. 10 Tutogen Medical, Inc.,(Amex: TTG ... human (allograft) and animal (xenograft) tissue, today announced,financial results for ... Summary of 2007 Highlights for the fiscal year ... 42%; -- Sales of dental products increased 38% ...
Cached Biology Technology:SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/15/2015)... 16, 2015 According to a ... Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, ... published by MarketsandMarkets, The Natural Language Processing Market is ... of 18.4% for the forecast period 2015-2020. ... F igures spread   through 155 P ...
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... 13, 2013) When a research team from Denmark ... cells (ASCs) versus bone marrow-derived stem cells (BMSCs) obtained ... coronary disease to regeneratively treat myocardial infarction in a ... cardiac function in the test rats while neither stem ...
... FEBRUARY 13, 2013 The experimental drug selumetinib may allow ... radioiodine (RAI), the most effective therapy for the disease, according ... Published in the February 14 issue of the New ... for patients with a disease that can have a poor ...
... neglected part of the obesity epidemic is that it ... pregnancy. Their offspring also tend to have higher birth ... risk of obesity and chronic diseases later in life. ... during pregnancy that may influence child obesity remain uncertain. ...
Cached Biology News:Stem cell source an important factor, impacting ability to treat myocardial infarction 2Drug shown to reverse radioiodine resistance in some advanced thyroid cancers 2Preventing obesity transmission during pregnancy 2
... ViaSure Kit is used in conjunction with the ... cells automatically. The ViaSure Staining Reagent uses ... Acridine Orange and Ethidium Bromide to identify live ... while the EasyCount Slide 6 Multi-well Slide ...
... Kit provides a powerful yet simple technology ... acids. The kit provides the heterobifunctional linkers ... quantifying conjugation efficiencies. It enables conjugation of ... other tags with a variety of proteins. ...
... Pierce offers maleimide activated carrier ... hapten-carrier conjugates. Imject Maleimide Activated Carrier ... have been preactivated with a heterobifunctional ... a stable, sulfhydryl-reactive carrier protein. ...
...
Biology Products: